Literature DB >> 1098361

Morphology and classification of malignant lymphomas and so-called reticuloses.

K Lennert.   

Abstract

There is general agreement as to the definition and subclassification of Hodgkin lymphomas, which is acceptable for practical reasons. However, the nature of the different types of Hodgkin lymphomas needs further consideration. On the other hand, today we are as far from agreement on non-Hodgkin lymphomas as ever before. Earlier European and American classifications have now to be reconsidered in the light of modern concepts of experimental immunology. It has become necessary to apply immunochemical and immunomorphological methods in addition to histological, histochemical, cytological, and ultrastructural techniques. Only such a complex approach has been able to provide new insight into the functional properties of the tumor cells. The result was a new lymphoma classification, which conforms to LUKES' concept in many respects. It was fundamentally accepted by a group of European lymphoma experts and has been condensed and modified in order to be applicable by as many lymphoma centers as possible. It has received the name "Kiel Classification" 1974. The main principles of the classification are as follows: 1. A distinction is made between malignant lymphomas of low-grade and those of high-grade malignancy; "-cytic", "-blastic" m.l. 2. The terms "sarcoma" and "leukemia" are avoided. All types of malignant lymphoma can be leukemic, however with differnt frequencies. All B-cell lymphomas can also show a monoclonal immunoglobulin increase ("paraproteinemia") in the blood, mostly of IgM. So-called macroglobulinemia of Waldenström is therefore not itself an etity, but instead a clinical syndrome. It has been shown that so-called reticulosarcoma is derived from immunoblasts, not from reticulum cells or histiocytes. The group of reticuloses also needs reconsideration. The term "reticulosis" is cytologically incorrect in most cases. Otherwise it refers to a group of diseases which we do not yet understand.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1098361     DOI: 10.1007/978-3-662-08456-4_1

Source DB:  PubMed          Journal:  Acta Neuropathol Suppl        ISSN: 0065-1435


  13 in total

1.  DNA content of mycosis fungoides cells.

Authors:  M Hagedorn; G Kiefer
Journal:  Arch Dermatol Res       Date:  1977-04-27       Impact factor: 3.017

Review 2.  Immunological characterization of lymphoproliferative disorders by membrane markers.

Authors:  H Huber; G Michlmayr; C Huber; M Falkensammer
Journal:  Klin Wochenschr       Date:  1976-08-01

3.  Proceedings of the congress of the Società Italiana di Neurochirurgia, Bari, September 20-October 1st, 1983. Abstracts.

Authors: 
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

4.  Morphology of lymphatic cells and of their derived tumours.

Authors:  F Rilke; S Pilotti; A Carbone; L Lombardi
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

5.  T cell type immunoblastic sarcoma diagnosed primarily by CSF cell membrane features.

Authors:  M Oehmichen; H V Gärtner; U Knittel-Jung
Journal:  Klin Wochenschr       Date:  1977-01-01

6.  Development of stroma in malignant lymphomas of the brain compared with epidural lymphomas. An immunohistochemical study.

Authors:  N Kochi; H Budka; T Radaszkiewicz
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

7.  Involvement of the central nervous system in malignant lymphomas.

Authors:  K Jellinger; T Radiaszkiewicz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-07-21

8.  Immunoblastic sarcoma with leukemic blood picture in the terminal stage of mycosis fungoides.

Authors:  E W Schwarze; P Ude
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975-12-31

9.  Primary leptomeningeal sarcomatosis. Clinicopathological report of six cases.

Authors:  H Budka; P Pilz; A Guseo
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849

10.  [Cerebral involvement in the Sézary syndrome (author's transl)].

Authors:  F Gerstenbrand; K Jellinger; D Lutz; E Maida
Journal:  J Neurol       Date:  1976-03-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.